Technologies Behind Biomarker Discovery and Development
Metabolomics, Proteomics, and Epigenetics
The Truth About Electronic Health Records
Why Oncologists Must Tailor Clinical Features to Their Needs
The Great Biomarker Chase
Promise and Pitfalls Along the Path to Personalized Care
The 4 Pillars: Foundation for Care
The Duke Cancer Institute
Drug Profiles
To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.
Latest in Literature
Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.
The Economics of Cancer Care in the United States
How Much Do We Spend and How Can We Spend It Better?
Putting Value Into Practice
Insights Into Value-Based Insurance Design in Oncology
Trying Something New: Episode Payments for Cancer Therapy
Radical Changes in Payment Incentives and Elimination of Low-Value Care
Payer Management of Oncology Gets Serious
Health Plans Continue to Seek Methods to Curtail Cancer Costs
Unraveling the Complexity of Drug Shortages
Grim Reality Is a Bitter Pill to Swallow: Interview with Michael P. Link, MD, ASCO President
Are We Winning the War on Cancer?
The Challenges Facing Oncologists Are Formidable
Targeted Products Yield Most Promising Results
A New Era in Targeted Treatment Has Begun
